MannKind develops dry powder inhaler for pulmonary hypertension treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. SBUX

Go back to MannKind develops dry powder inhaler for pulmonary hypertension treatment

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

May 6, 2026 6:30 AM EDT

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited Therapeutics plans to be the primary manufacturer of ralinepag DPIMannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:... More